Disease Detail

ID DOID:50745
Name diffuse large B-cell lymphoma
Definition A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma diffuse large B-cell lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MYD88 wild-type ST2825 diffuse large B-cell lymphoma predicted - sensitive detail...
EZH2 Y641N UNC1999 diffuse large B-cell lymphoma sensitive detail...
Unknown unknown Birabresib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Sirolimus + UCN-01 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown IT-901 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown SEL24-B489 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ibrutinib + SEL24-B489 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Copanlisib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Parsaclisib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Itacitinib + Parsaclisib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ublituximab + Umbralisib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown MLN0905 + Rituximab diffuse large B-cell lymphoma not applicable detail...
Unknown unknown MLN0905 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Cerdulatinib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Fostamatinib diffuse large B-cell lymphoma no benefit detail...
Unknown unknown ST7612AA1 diffuse large B-cell lymphoma not applicable detail...
MYD88 act mut Tomivosertib diffuse large B-cell lymphoma predicted - sensitive detail...
Unknown unknown Tomivosertib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown CUDC-907 diffuse large B-cell lymphoma not applicable detail...
MYD88 L265P N/A diffuse large B-cell lymphoma not applicable detail...
EZH2 Y641N ACY-957 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S ACY-957 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N Vorinostat diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S Vorinostat diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N ACY-957 + GSK126 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S ACY-957 + GSK126 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N ACY-957 + DZNeP diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S ACY-957 + DZNeP diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641S GSK126 diffuse large B-cell lymphoma decreased response detail...
EZH2 Y641N GSK126 diffuse large B-cell lymphoma no benefit detail...
EZH2 Y641S DZNeP diffuse large B-cell lymphoma decreased response detail...
EZH2 Y641N DZNeP diffuse large B-cell lymphoma predicted - sensitive detail...
EZH2 Y641N ACY-957 + Doxorubicin diffuse large B-cell lymphoma sensitive detail...
EZH2 positive Tazemetostat diffuse large B-cell lymphoma predicted - sensitive detail...
Unknown unknown CPI-0610 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown BGB-3111 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown GS-5829 + Venetoclax diffuse large B-cell lymphoma not applicable detail...
Unknown unknown TTI-621 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Abexinostat diffuse large B-cell lymphoma not applicable detail...
MYD88 L265P Vorinostat diffuse large B-cell lymphoma sensitive detail...
Unknown unknown Acalabrutinib + ACP-319 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown AT-7867 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown OPB-111077 diffuse large B-cell lymphoma not applicable detail...
EZH2 Y646F EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y646N EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y646S EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 F120L EZH2 Y111N EI1 diffuse large B-cell lymphoma resistant detail...
EZH2 F120L EZH2 Y111N EED226 diffuse large B-cell lymphoma sensitive detail...
EZH2 Y641N EED226 + EI1 diffuse large B-cell lymphoma sensitive detail...
EZH2 mutant A-395 diffuse large B-cell lymphoma sensitive detail...
Unknown unknown Ibrutinib + Venetoclax diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Fenretinide diffuse large B-cell lymphoma not applicable detail...
Unknown unknown JCAR017 diffuse large B-cell lymphoma not applicable detail...
PTEN loss Idelalisib + MK2206 diffuse large B-cell lymphoma predicted - sensitive detail...
PTEN loss GSK2334470 + Idelalisib diffuse large B-cell lymphoma predicted - sensitive detail...
Unknown unknown Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine diffuse large B-cell lymphoma no benefit detail...
Unknown unknown Umbralisib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Fostamatinib + Silmitasertib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ibrutinib + Silmitasertib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ibrutinib diffuse large B-cell lymphoma not applicable detail...
MYD88 L265P Ibrutinib diffuse large B-cell lymphoma resistant detail...
Unknown unknown SNS-510 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Tisagenlecleucel diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Ibrutinib + PQR309 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown LAM-002A diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Buparlisib + Ibrutinib diffuse large B-cell lymphoma not applicable detail...
Unknown unknown EBI-2511 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Loncastuximab tesirine diffuse large B-cell lymphoma not applicable detail...
Unknown unknown STRO-001 diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Hu5F9-G4 + Rituximab diffuse large B-cell lymphoma not applicable detail...
Unknown unknown Bendamustine + Polatuzumab Vedotin + Rituximab diffuse large B-cell lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00001337 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Recruiting
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated
NCT00918463 Phase II Dasatinib A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated
NCT00978432 Phase II Everolimus + Panobinostat Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated
NCT01177397 Phase Ib/II CC-223 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01193842 Phase Ib/II Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed
NCT01334502 Phase I Everolimus Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma Completed
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting
NCT01431209 Phase II Ruxolitinib Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma Active, not recruiting
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Active, not recruiting
NCT01453205 Phase II Cisplatin + Cytarabine + Dexamethasone Carboplatin + Etoposide + Ifosfamide Rituximab MEDI-551 A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed
NCT01691898 Phase Ib/II Obinutuzumab + Pinatuzumab Vedotin + Rituximab Pinatuzumab Vedotin + Polatuzumab Vedotin + Rituximab Obinutuzumab + Polatuzumab Vedotin A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS) Completed
NCT01719250 Phase I Buparlisib Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Active, not recruiting
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation
NCT01854606 Phase Ib/II AEB071 + Everolimus Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Completed
NCT01855750 Phase III Ibrutinib Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT01859819 Phase II Cytarabine + Rituximab Treatment for Advanced B-Cell Lymphoma Recruiting
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed
NCT01938638 Phase I BAY1143572 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Completed
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Active, not recruiting
NCT01955499 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT01959698 Phase Ib/II Carfilzomib + Rituximab Carboplatin + Etoposide + Ifosfamide Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Recruiting
NCT01992653 Phase I Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab vedotin-piiq Obinutuzumab A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Completed
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Recruiting
NCT02000934 Phase I TAK-659 A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Active, not recruiting
NCT02029443 Phase Ib/II Acalabrutinib ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting
NCT02031419 Phase I CC-122 + CC-292 CC-223 + CC-292 CC-122 + CC-223 Rituximab Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma Active, not recruiting
NCT02055820 Phase I Venetoclax Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Obinutuzumab A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma Active, not recruiting
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Recruiting
NCT02073097 Phase Ib/II Carfilzomib + Rituximab Cyclophosphamide + Doxorubicin + Vincristine Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma Recruiting
NCT02077166 Phase Ib/II Ibrutinib + Lenalidomide + Rituximab Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02082977 Phase I GSK126 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma Terminated
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Terminated
NCT02138786 Phase II Selinexor Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT) Terminated
NCT02141451 Phase Ib/II INCB7839 + Rituximab ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL Active, not recruiting
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Active, not recruiting
NCT02181218 Phase I Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Active, not recruiting
NCT02203526 Phase I Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal-doxorubicin + Temozolomide Cytarabine Rituximab Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma Recruiting
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed
NCT02219737 Phase I Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed
NCT02220842 Phase I Atezolizumab + Obinutuzumab A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Active, not recruiting
NCT02226965 Phase II PNT2258 Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL Unknown status
NCT02227251 Phase II Selinexor Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL) Active, not recruiting
NCT02229981 Phase Ib/II ABC294640 An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma Withdrawn
NCT02252146 Phase Ib/II IMO-8400 Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation Completed
NCT02257567 Phase Ib/II Bendamustine + Rituximab Polatuzumab vedotin-piiq Obinutuzumab A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Recruiting
NCT02282358 Phase Ib/II Mocetinostat Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Active, not recruiting
NCT02303392 Phase I Ibrutinib + Selinexor Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Recruiting
NCT02315326 Phase Ib/II Ibrutinib Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) Recruiting
NCT02323230 Phase II Cyclophosphamide + DPX-Survivac A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL Unknown status
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02343536 Phase I Cyclophosphamide + Prednisone + Rituximab + Vincristine Azacitidine A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma Active, not recruiting
NCT02348216 Phase Ib/II KTE-C19 A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) Recruiting
NCT02361346 Phase I MT-3724 PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia (MT-3724NHL001) Recruiting
NCT02362997 Phase II Pembrolizumab Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL Recruiting
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Active, not recruiting
NCT02391116 Phase II Copanlisib Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed
NCT02399085 Phase II Lenalidomide + MOR208 A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Active, not recruiting
NCT02401048 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Active, not recruiting
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn
NCT02420795 Phase Ib/II ONC201 Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Recruiting
NCT02436707 Phase II Ibrutinib Cisplatin + Dexamethasone + Gemcitabine + Rituximab Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma Recruiting
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated
NCT02443077 Phase III Cyclophosphamide Carmustine + Cytarabine + Etoposide + Melphalan Ibrutinib Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Suspended
NCT02445248 Phase II Tisagenlecleucel Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET) Active, not recruiting
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated
NCT02471911 Phase I Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma Recruiting
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Recruiting
NCT02530125 Phase II Pidilizumab Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission Terminated
NCT02531308 Phase II Metformin Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Pegfilgrastim Rituximab Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) Terminated
NCT02532192 Phase I Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma Withdrawn
NCT02541565 Phase I Pembrolizumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Rituximab Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma Recruiting
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Recruiting
NCT02549651 Phase I Durvalumab + Tremelimumab Durvalumab AZD9150 + Durvalumab MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) Completed
NCT02564744 Phase II IMGN529 + Rituximab Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL Recruiting
NCT02570542 Phase II Plerixafor Carmustine + Cytarabine + Etoposide + Melphalan Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
NCT02572453 Phase II Onalespib AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma Recruiting
NCT02576990 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170) Active, not recruiting
NCT02580552 Phase I MRG-106 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Recruiting
NCT02581631 Phase Ib/II Brentuximab vedotin + Nivolumab A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) Active, not recruiting
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Terminated
NCT02596971 Phase I Atezolizumab + Obinutuzumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Bendamustine Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02600897 Phase Ib/II Lenalidomide + Obinutuzumab + Polatuzumab Vedotin A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02611323 Phase Ib/II Obinutuzumab + Polatuzumab Vedotin + Venetoclax A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02624986 Phase Ib/II Idasanutlin + Obinutuzumab A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Terminated
NCT02628405 Phase Ib/II Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Rituximab R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Recruiting
NCT02631044 Phase I JCAR017 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Recruiting
NCT02636322 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Ibrutinib + Lenalidomide + Rituximab Prednisone A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Active, not recruiting
NCT02658968 Phase I Betalutin Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) Recruiting
NCT02674750 Phase II CUDC-907 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations Active, not recruiting
NCT02681302 Phase Ib/II Ipilimumab + Nivolumab Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001) Recruiting
NCT02684617 Phase I Dinaciclib + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) Active, not recruiting
NCT02698189 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) Active, not recruiting
NCT02700022 Phase I Alisertib Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Terminated
NCT02701673 Phase Ib/II Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Withdrawn
NCT02706405 Phase I Cyclophosphamide + Durvalumab + JCAR014 JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting
NCT02729896 Phase Ib/II Obinutuzumab + Polatuzumab Vedotin + Rituximab Atezolizumab + Obinutuzumab + Polatuzumab Vedotin A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT02734771 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn
NCT02756247 Phase I Buparlisib + Ibrutinib A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Active, not recruiting
NCT02760485 Phase Ib/II Ibrutinib + Itacitinib A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02763254 Phase II CMD-003 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC) Terminated
NCT02763319 Phase II Bendamustine + MOR208 Bendamustine + Rituximab A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) Recruiting
NCT02776813 Phase I ACTR087 + Rituximab Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Active, not recruiting
NCT02793583 Phase II Umbralisib Ublituximab + Umbralisib Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL) Recruiting
NCT02815397 Phase II Metformin DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma Terminated
NCT02874404 Phase II Ibrutinib + Umbralisib TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Recruiting
NCT02914938 Phase I ME-401 ME-401 + Rituximab A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting
NCT02926833 Phase Ib/II Atezolizumab + KTE-C19 A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) Active, not recruiting
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Recruiting
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting
NCT02951156 Phase III Avelumab + Azacitidine + Utomilumab Avelumab + Rituximab + Utomilumab Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab Avelumab + Bendamustine + Rituximab Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Active, not recruiting
NCT02953509 Phase Ib/II Hu5F9-G4 + Rituximab Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Recruiting
NCT02961816 Phase II Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Withdrawn
NCT02998476 Phase II Parsaclisib A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Active, not recruiting
NCT03003520 Phase II Cyclophosphamide + Doxorubicin + Durvalumab + Lenalidomide + Prednisone + Rituximab + Vincristine Cyclophosphamide + Doxorubicin + Durvalumab + Prednisone + Rituximab + Vincristine A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Recruiting
NCT03019640 Phase II Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Recruiting
NCT03028103 Phase I Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects Active, not recruiting
NCT03036904 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) Recruiting
NCT03064867 Phase I Carboplatin + Etoposide + Ifosfamide + Rituximab + Venetoclax Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Suspended
NCT03106428 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies Recruiting
NCT03123393 Phase II TAK-659 TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT03135262 Phase Ib/II Idasanutlin + Rituximab + Venetoclax Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin + Obinutuzumab + Rituximab + Venetoclax A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT03136497 Phase I Ibrutinib + Rituximab + Venetoclax A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting
NCT03150329 Phase I Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma Recruiting
NCT03153462 Expanded access Cyclophosphamide + Fludarabine + KTE-C19 Axicabtagene Ciloleucel Expanded Access Study Available
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03189836 Phase I ACTR707 + Rituximab Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Recruiting
NCT03205046 Phase Ib/II Acalabrutinib + Vistusertib A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies Active, not recruiting
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03220022 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Ibrutinib + Pegfilgrastim + Prednisone + Rituximab + Vincristine Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Recruiting
NCT03255018 Phase II Pembrolizumab Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas Recruiting
NCT03255096 Phase I Rituximab + TEN-010 + Venetoclax A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Not yet recruiting
NCT03263026 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Enzastaurin Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 Recruiting
NCT03274492 Phase III Polatuzumab vedotin-piiq Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Recruiting
NCT03283202 Phase Ib/II CC-122 + Cyclophosphamide + Prednisone + Rituximab + Vincristine Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors Active, not recruiting
NCT03297424 Phase Ib/II PLX2853 A Study of PLX2853 in Advanced Malignancies. Recruiting
NCT03305445 Phase Ib/II Ipilimumab + Nivolumab Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Recruiting
NCT03309878 Phase Ib/II Pembrolizumab Mogamulizumab + Pembrolizumab Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas Recruiting
NCT03311958 Phase I Nivolumab Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance Recruiting
NCT03316573 Phase II Pembrolizumab A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Recruiting
NCT03321643 Phase I Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Recruiting
NCT03349450 Phase II Cyclophosphamide + DPX-Survivac + Pembrolizumab DPX-Survivac DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL) Recruiting
NCT03357627 Phase I TAK-659 + Venetoclax A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma Recruiting
NCT03365791 Phase II LAG525 Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Active, not recruiting
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated
NCT03391466 Phase III KTE-C19 A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) Recruiting
NCT03418038 Phase II Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Recruiting
NCT03424122 Phase I Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Recruiting
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting
NCT03440567 Phase I Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab Avelumab + Ibrutinib + Rituximab + Utomilumab Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Recruiting
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting
NCT03467373 Phase I Tocilizumab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine RO7082859 Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + RO7082859 + Vincristine Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + RO7082859 + Vincristine A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas Recruiting
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Recruiting
NCT03484819 Phase II Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Recruiting
NCT03488251 Phase II Gemcitabine + MT-3724 + Oxaliplatin PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting
NCT03558750 Phase Ib/II Lenalidomide + Nivolumab + Rituximab Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma Terminated
NCT03586024 Phase Ib/II Pembrolizumab Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL) Recruiting
NCT03589469 Phase II Loncastuximab tesirine Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting
NCT03598608 Phase Ib/II MK-4280 + Pembrolizumab Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Recruiting
NCT03610724 Phase II Tisagenlecleucel Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) Recruiting
NCT03630159 Phase I Pembrolizumab + Tisagenlecleucel Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA) Recruiting
NCT03645395 Phase II Lenalidomide + MT-3724 PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) Recruiting
NCT03671018 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Cyclophosphamide + Prednisone + Rituximab + Vincristine Bendamustine + Polatuzumab Vedotin + Rituximab Bendamustine + Obinutuzumab BTCT4465A + Polatuzumab Vedotin BTCT4465A Obinutuzumab Tocilizumab A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Recruiting
NCT03677141 Phase Ib/II Tocilizumab Cyclophosphamide + Doxorubicin + Polatuzumab Vedotin + Prednisone + Rituximab BTCT4465A + Cyclophosphamide + Doxorubicin + Polatuzumab Vedotin + Prednisone BTCT4465A + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Recruiting
NCT03677154 Phase Ib/II BTCT4465A + Tocilizumab A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy Recruiting
NCT03682796 Phase I TRPH-222 Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Recruiting
NCT03685344 Phase I Durvalumab + Loncastuximab tesirine Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Recruiting
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting
NCT03703167 Phase I Ibrutinib + Lenalidomide + Rituximab Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) Recruiting
NCT03704714 Phase Ib/II Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Recruiting
NCT03742258 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TAK-659 + Vincristine Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Recruiting
NCT03797261 Phase I AMG 176 + Venetoclax A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies Recruiting
NCT03876028 Phase I Ibrutinib + Tisagenlecleucel Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients Recruiting
NCT03884998 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma Recruiting
NCT03892044 Phase I Duvelisib + Nivolumab Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Not yet recruiting
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Not yet recruiting
NCT03934814 Phase I TJ011133 Pembrolizumab + TJ011133 Rituximab + TJ011133 Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Recruiting
NCT03939182 Phase Ib/II Abexinostat + Ibrutinib Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma Recruiting
NCT03955783 Phase I Selinexor + Venetoclax Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies Not yet recruiting
NCT03990961 Phase II Pembrolizumab Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) Not yet recruiting
NCT03995147 Phase II Cyclophosphamide + Doxorubicin + Pembrolizumab + Prednisone + Rituximab + Vincristine Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma Not yet recruiting